NewsRoom Articles - Page 98 of 103 - CanadianCannabisWire

FridayOct 20, 2017 9:19 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) to Hold Web-Meeting on November 1

Web-meeting scheduled for November 1, 2017, at 4:15 p.m. ET 19 patents filed encompassing 44 countries Patents cover broad range of lipophilic bio-actives including cannabinoids, vitamins and other pharma Patented lipophilic delivery system proven to improve bio-absorption The medical effectiveness of cannabinoids is no longer in question, and the cannabinoid market proliferates ever faster as more people realize the therapeutic benefits. However, the human gastrointestinal tract just doesn’t absorb cannabinoids effectively, and much of what is ingested is subsequently excreted by the body, causing onset times and efficacy to vary wildly. With 19 patent applications filed internationally covering 44 countries,…

ThursdayOct 19, 2017 12:52 pm

InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) Biosynthesis Technology Demonstrates Robust Diversity

Biosynthesis technology making strong advances Two promising pipeline candidates Inclusion in the CSE25 Index InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) continues down the fast track with its proprietary technology for the microbial biosynthesis of cannabinoids (http://cnw.fm/uIL78). The company recently announced it has enabled the production of all four "gateway" cannabinoids using genetically engineered microorganisms. From these gateway substrates, production of all 90+ cannabinoids is possible via biosynthesis. InMed’s breakthrough stands to make the production of cannabis derivatives, including THC, CBD and trace cannabinoids, a much more commercially feasible proposition. The Company currently has two lead drug candidates that employ…

ThursdayOct 12, 2017 9:30 am

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Oral Digestion Technology Needs No Sugar Coating

Delivery technology with application to all non-psychoactive cannabinoids Company is an enabler rather than competitor to hemp oil producers Revenue from licensing DehydraTECH oral digestion technology Thanks to Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), there’s no need for a spoonful of sugar to help the medicine go down. This innovative biotech has developed technology that masks the strong taste and odor of hemp oil products, eschewing the need for artificial sweeteners, which tend to come with their own fallout to heart and health. Lexaria’s DehydraTECH oral digestion technology is a ‘back office’ process that solves the taste and odor…

TuesdayOct 10, 2017 12:53 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Bioabsorption Tech Boosting Development of CBD Products

Technology improves absorption of cannabidiol and bioactive compounds into the bloodstream It is now being used on all non-psychoactive cannabinoids and applied to edibles and health food products Patents have been awarded in the U.S. and Australia and are pending in 44 countries Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds. Its patent-protected technology has improved the ability of cannabinoid-products companies to deliver active ingredients to the body. With patents pending for tetrahydrocannabinol and other psychoactive cannabinoids (plus nicotine and non-steroidal anti-inflammatory drugs), the current technology…

MondayOct 09, 2017 11:52 am

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Paving the Way as Biosynthesis Promises to Revolutionize Drug Development

Forbes predicts medical marijuana sales to reach $13.3 billion by 2020 Biotech/pharma market could surpass $20 billion by 2020, per estimates from Viridian Capital Advisors InMed’s biosynthesis process uses DNA and E. coli to produce cannabinoids that are identical to the 90+ found in nature The company’s pipeline drugs, focusing on rare dermatological diseases, glaucoma and topical pain treatments, are advancing toward clinical trials There may be many companies exploring cannabinoid biosynthesis, but one in particular stands out. InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) has created a revolutionary process that is poised to impact the cannabinoid market. It’s just one…

MondayOct 09, 2017 9:06 am

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Scaling Up to Meet Impending Spike in Cannabis Demand

Ever at the forefront of Canada’s cannabis market, ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) was among the very first companies to obtain a cannabis production license in that country and has since been working to change the face of medical cannabis—both in Canada and globally. ABcann’s group of companies is working toward the aim of becoming the first cannabis pioneers to produce repeatable, standardized, plant-based medicines around the world. Every variable of ABcann’s cannabis growing, curing and harvesting process is computer-monitored and controlled. This high-tech indoor growing environment consistently yields a superior product that is clean, steady and repeatable—something…

ThursdayOct 05, 2017 11:07 am

Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) Enters Agreement for Sustained Release Cannabinoid Formulation

Companies collaborating on development of patent-pending sustained release oral cannabinoid formulation Formulation doubles or triples time period in which cannabinoid doses maintain their therapeutic effects Formulation enables better regulation of dosing schedules and improvement of patient compliance Emblem Corp. (TSX.V: EMC) (OTC: EMMBF), a company licensed to cultivate and sell medical marijuana in Canada under the Access to Cannabis for Medical Purposes Regulations, has entered into a collaboration and licensing agreement with Canntab Therapeutics Limited to collaborate on the preclinical formulation, clinical development, regulatory approval, manufacturing and commercialization of Canntab’s patent-pending oral sustained release formulation for cannabinoids. Through this agreement,…

FridaySep 29, 2017 12:52 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Tech Discussed at “Cannabis in the Capital Markets” Event

Clinical studies of TurboCBD™ a topic of discussion at Canadian Securities Exchange-sponsored “Cannabis in the Capital Markets” event Patents cover variety of lipophilic bio-actives, including cannabinoids, nicotine and vitamins Growing portfolio of intellectual property includes 19 patents filed across 44 countries Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), through its proprietary technology for delivering bioactive compounds in lipid formulations, offers licensed partners the ability to include cannabidiol (CBD) in a variety of ingestible products appropriate for medical patients and recreational users alike. In a new report, Grand View Research, Inc., states that the global market for medical cannabis alone is…

WednesdaySep 27, 2017 3:19 pm

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Targets Specific Diseases with its Proprietary Biotechnologies

Provisional patent application protects unique process yielding pharmaceutical grade, bio-identical cannabinoids Proprietary research allows production of synthetic cannabinoids for therapeutic use with certain diseases Early stage clinical trials are expected to begin in 2018 for a drug targeting a rare children’s skin disorder Imagine having a painful disease that causes your skin to blister at the slightest minor injury. Even just scratching an itch or accidentally rubbing against a rough object could cause peeling blisters and acute suffering. Epidermolysis bullosa, a genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States, currently has…

MondaySep 25, 2017 3:46 pm

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Attains $43M in Capital, Plans Significant Production Capacity Increase

Aaron Keay, CEO, says plans set for greater production capacity and strategy for global distribution in emerging markets Expansion of ABcann’s Vanluven facility underway, along with construction of the company’s 150,000 sq. ft. Kimmett facility Napanee, Ontario-based firm uses proprietary plant-growing technology and is pursuing opportunities in Australia and Germany ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) achieved working capital of $43 million from multiple financings, including private placements and strategic partnerships, during the six months ended June 30, 2017, it announced on August 29 (http://cnw.fm/1BXpf). ABcann manufactures and distributes medical cannabis under a license issued by Health Canada to…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 905.674.5977